FGEN vs RCL · rev $29.6M vs P/E 26, rev $9.28B
FibroGen Inc (FGEN) versus Royal Caribbean Cruises Ltd (RCL) — a side-by-side from cached financials, not a winner call.
FibroGen Inc (FGEN) is a biotechnology company listed on NASDAQ.
Royal Caribbean Cruises Ltd (RCL) is a travel services company listed on US.
Latest reported FGEN revenue for 2024-12-31 was $29.6M. Net income was -$47.6M. Revenue was down 36.7% from 2023-12-31 to 2024-12-31. FGEN currently screens at market cap $39.3M.
Latest reported RCL revenue for 2026-06-30 was $9.28B. Net income was $2.07B. RCL currently screens at market cap $85.57B and trailing P/E 25.7.
FGEN currently screens at market cap $39.3M. RCL currently screens at market cap $85.57B and trailing P/E 25.7.
Not investment advice. Open the FGEN and RCL stock pages for the full models.
Not investment advice.